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summary 
Plasma factor XIII (plasma protransg luraminase') cirClll ale~ as an 
A.B, tetramer bound 10 the "I' variant ch aill~ of fibrinogen "2". During 
douing the A subll nil.s of fXJIJ are cleaved hy thrombin to form fXIIIa 
IIrJllsglutaminasc) and in the prcsc-nce of calcium ions, act ivated A} 
~ubunig dissociate fmmlhc B SUbllllits. When purified pl:lsma IX III or 
r~c[ll11hin [[ nt cellular fUCIO[' XIlI (A) was incubated with fibri 110gen in 
the prese nce of calcium ions (:250 11M! a non-syneri7.ing gel formed 
concomitant with f()nl latioll of)' dimers, followed by A)' polymers, and 
erenlllully -y rrimers and "I tetramers. As is the case of fXlTla., the 
fX lII- mediated crosslinking rate was cnhancer1 in the pn:scDce of 
Ih iols. After an initia l lag period, fXlll catalyzed fibrinogen cross-
linking. at ~ 75% of the rate of fXllIa under typical crossJinking condi-
tions ( lilt] Loewy u/ml, 5 mM CaCl, & 500 ~M DTT). hbrin W"' 
crosslinked about 8 times more rapidly by Ixm than was fi bli llogen, 
and aftl' r an inilial Jag peliod fX lll crosslink ed fi bl;n at nearly the same 
rale as tX lIla. SubslilUti ng plasma for pu rified fXIlI as the somcc for 
fX 1I1 resulted in robu st t'ihrinogen cross linking activity. In contrast to 
the high level of fXIJI-mediatcd crossJi nking activity ohserved wilh 
librinogen or fibr in <IS sllbstraleS, when tmnsgiliLaminatiol1 was meas-
ured using cadaverine incorporation i[lIo casein, fX lll was 30-told less 
act ive than fX llIil. Thus. factor XIII (jisp\ays constillllj ve enzymatic 
activity with respect 10 fib rinogen and fib rin. The fCsuhs further indicalt: 
:hat unClcaved lXIIl in plasma provides a potent source of readily 
<!vai lable crosslinkillg activiLY in clotting blood. Fibrinogen 2, whose 
~'chtlil\s bind fXlIl B subun iL'i: W,lS crosslinked 3.5 times more sJol,l.lly 
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by fXlH than wa;; tihrinogcn 1 (Jacking -y' chains), suggcsling Ihat 
complcx formation bel\I;'ccn fihri nogen 2 and plasma I"XIII plays a 
~ignincant role in down-regulating potenti al plasma fXIII- medimcu 
crossli nking activity. Since fibrin is a con~jlkrably better substrate for 
tXII I th.m is fi brinogen, the rate at wh ich crosslinking takes place in a 
tibrinogell-conl.:1illing plasma envi ronment iii much lower than it would 
Ix il" I'ibrill were present. 
Introduction 
Hbrinogt!n is a lridoillainal di!>ulfidc linked protein comprised of 
two ~ymmetl;cal halves, each composed fif three polypeptide chain:-
termed /\0:, B~, and y (1-3), Human lihri llogcll can be separated by 
ion exchangc chromalngraphy into lWO major fract ions, fibrinogen 1 
("peak I fibrinogen") 311d fi brinogen 2 ("peak 2 fihrinogen") (4, 5), 
The twu fi brinogens differ from ~ach olher with respect 10 th~ compo-
sition of their 'Y chains. Fibrjnogen I contains two "'fA ch<1ins \-',·hich are 
coropri'led of 411 amino acids . Hetcrou inlt:: [;c fibrinogen 2 molecllles 
each contain one "/,I, ami one ,,/ ' chain (6 , 7) . The variant y ' chain is 
longer (427 residues), and has a more anioni c, c-<'uboxyl H~lm il1al 
sequence than the "fA ch"in beyond position 4()X (Ii) . Factor Xlii has 
been shown 10 bind 10 the )- chains ill fibrinogen 2 (9) and thrombin 
has also been shown to biod to Ihe Slime anionic -y'extcnsion of fibrin 2 
( III), 
Following thc rapid thrombin-mediated cleavage offihrinopcplidl": A 
(11 -15) [l.lld s]m·ver c1 ea\'age of fi brinopeptidc B (\ 6- 1R), fibrll.l as~embly 
commences with formatiolJ or doubl{! stranded twisting fi.brils in which 
fibrin molecu les arc "'lTanged in a Maggered overlapping manner 
(19-26). Subscquently, laleral fibril assoc iation~ oct.:ur, resulting i.n 
thick fibcr~ (22, 26-2H). Concomitant witll cOllverting fibrinogen to 
fibrin, thrombin activates factor XTTlto facto]' XIIIa. In the presence of 
fXllla and Cal+, fibri n undcrgoci intermolecular covalent crosslinking 
by l(lIma tion of E-amino(,,:,-glut..1myl) lysi ne isopeptide bonds (29, 30). 
Crossli nking of 'Y chains within fibrils OCCllrs belween properly aligned 
chains at lysine 406 of one "I chain, and a glutamim: at IX)sitioll 398 or 
399 of another to form 'Y djmcr~ (31 ,32). Intermolecular crosshnk ing 
Ix:lw~t:1l u chaills creates oiigomers and larger a: chain polymer'i and 
Ol'curs more slowly than "I dimeriz-ation (32, 33). Gamma trimer'> and "I 
tetramcrs fonn after more prOlonged illt.:ubalion (19). l-'aclor XlIla can 
also cro)sl ink frhrinogen, alheit at a somewhat slower rate (34. 35). 
Crosslinked fibrinogen forms a transl ucent. non-syncl'i7.ing gel, that is 
[lssociatcd with "I di mer formation (34, 35). 
Plasma factor XfII (protransglu taminasc, is a noncovalent tct ralilt ric 
protein complex composed of IWO pairs or subun it chains termed "A" 
ami "8", rcspc"Ctive1y (36~3S). Thrombin cleavage at position 37 of the 
A ~ ubllnit~ (39-4 1) leads to format ion of Ihe active enzyme. factor XlTJa 
(transgllllaminase), which itself reqLlires Ca2~ fo r dissociation or the 
act ivated sublmits {A 2:~ ) from the B subunit~ and ror full expression of 
ils cJWlylie acti vity (42-40). Act ivation of rxm an(j Ihe activity of 
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fXlTIa is promoted in the presence of fibrinogen 1:45-51) amI perhaps 
eveUlllore spe,cilically, by fibrin (47-54), Inhibition offibrinpolymer~ 
izatioll with the peptide GPRP, eliminates the enhancing effect of 
fibrin on fXlII activation (49, 52, 55), sllggesting that the fihrin effect 
is mediated through formation of a ternary complex among thrombin, 
fibrin, and factor XIII (jlJ), 
Factor XIII can be activated independently of thrombin. Calciulll ion 
concenU'<ltions greaLcr [han 100 111:\1 activate fXlll and expose the 
active site cysteine to suHllydrylmodification (45). Chaotropic anions, 
such as p-toluencsulfonate or thiocyanate, reduce the calcium iOIl 
requiremcnt for thrombin-independcnt activation or faCIal' XIII to about 
50 mM (56). BlombUck ct al. (57) also notcd that thc fXlII "zymogen" 
in the presence of a supraphysiological Ca~c- concentration (20 111M) 
plus a reducing agent caused gelation of fibrinogen, suggesting that 
JXIII had intrinsic crosslinking activity. During the course of earlier 
studies un the interaction between fibrinogen 2 and factor XIII (9). we 
observed thaL mixtures of fibrinogen and fXIIl formed gels when ex-
posed to near physiological concentrations (5 my1) of Ca> (unpub-
lished observations). In this prcsent study those preliminary observa-
tions ha\:c been extended by thoroughly characterizing the crosslinking 
activity of the plasma ractor XIII "zvmogen" (A)B,) as well as that or 
the cellula[' fmlll of factor xnr (A2).- ~ - -
Materials and Methods 
Trisl, glycine, Cool1lassie Brilliant Blue R250. N-ethylmaleimide. and OTT 
\\/el1: pmchased from /i.ldrich Chemical Co" \filwauKee, \VI. Tr;;sylol (aproti-
nin) was obtaincd from Miles Inc., K:ll1kakee, IL, '+C-cadaverinc ,md NH-
dimetIlyJcasein was acquired from Sigillil Chemical Co" St. LOllis, ),,10. ami 
DE-52 cellulose \vas ti'Ol11 \Vhatman l[lC .. Clifton, l\iJ. Human {'( thrombin 
(31 SS lI/rng) was obtained from EllLYllle Research LahOl-alories, Soulb Rend, 
IN. Recombinant Cellular factor XIU (A") was the kind gift of Paul Bishop 
(ZymoGenetics, Seallle, WA) and bad a specific activity of 1550 Loewy u/mg 
when assayed as thrombin activated fXllla. Other chemicals ',vel'e the higllest 
pwity available from commercial soure~s. 
Hllman fibrinogen was isolated from p{)Oleci citrated plilsma by glycine 
precipitation (5S), and further purified as previously described (59). [ 2 m1rino-
gen was sllbfract\Onated into fibrinugcn I (y .. -"YA) and fibrinogen 2 (y\-,{') 
by chwmalOgraphy 011 DE-52 (91. Fibrinogen 1 is factor XIII frce, sincc all of 
tbe contmllinaLi[lg plasma ['Xlii eluLes with fibrinogen 2 (9). The fibrinogen 2 
used in tllCse studies contained Icss than 5 Loev,"y units of lXlll actiYity per 
milligram of total protein. Soluble fihrin monomer Vias prepmed by the method 
of Rei itsel' et ~ll. [OO}. ri hl'inogen and ~olllble fibrin concentrations Wl'rc dder-
mined spectrophotomelrinilly at 280 nm using an absorhanee coefficient 
V\:~;~,J of lSI (61) 
Factor XIII 'was purified from pooled 11UnlUl1 pla~mu (62) and assayed 011 
fXIJJ free fibrin substrates (prepared from fibrinogen 1) in tI1C prese-nee of 
10 mM CaCl:, as lhrombin-activated fXIIIa as described by Locwy el aL (63), 
Factor XIII concenlratiom were determined spectmpl10tometrically at 280 11m 
lIsillg an cxtinction coefficient (A](~", ) of 1.1.N (l6)_ The specific erosslinking 
activitie~ or the (hromhin-activated [XIII preparations ,,'cre bet\'ieen 2100 and 
2300 Loewy u/mg_ TIle [1oobl human pbma (fibrinogen level, 2_S3 Illg/llll) 
used in thesc studies contained 105 Loe .... ) u/mll'actor XIII ~li:tivity and single 
donor plaslllas range from SS to 120 u/ml. PlII-i fieL! I'aclor XIII zymogen f loaded 
at 2D Ilgiband/lane) was re~olved into tvm bands by non-reducing SUS-PAGE 
(M), the A sulmnit 01'75 kO and the B .'il1bunit of 79 kD (36, (5), 1\0 active A 
subunit (A':'; 72 kD) was detectcd in the~e preparations (semitivity «), 1 l1.g/ 
b,mdllane or lc.,s than 0,511(, of the A ~ublll1it population), XIII \vas aClivaled to 
XIlI~ by incuhatiun with tllrornbin (10 \liml) (34) for 30 min at JT C and 
the thrombin then inactivated by incubating with a 5 rold excess of hirudin 
(50 uiml'! (35). SDS-PAGE of Xilia revealed tv.'o bands, the active A'" subunil 
(72 kDJ and the 13 subunit O() kD} (36, 65). 
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Typicill crm,linking reaction mixtures contained fibrillugell I U lll!:!l, I ' 
-0 MI' I!J(- (' . - ~n!1n ) 11:: _ . ns, . J mtv1 Na J, .:'i ~llivl ~~I~L~, 0,;,) Illi\v'~ ,OTT, U.S m~T P\lSF 
10 KIUmI Trasylol, pH 7.4. LrossllIlklng was Illitiated by adding rXlli 
(100 Loewy u/ml; 0.124 J1.M) (lm\lIlcubatlllg at room temperatllre, 'nlC c, 
linking cunditi(}n~ were modi tied for certain experiments by varyii'.[~ the t~~:1 
concentmtJOn (0 to 2(){) Loev ... y 1I/rnl). the calc]lJm 1011 conccnlnllion 10 
l() mM). rbe DTI cOllccnuation (0 w 5 mM), by employing difl'cIl'llt redl'(:[n~ 
agents (~-mercaptocthanol m cysteine), by llsing fihrinogen 2, hy llsillg ~()ILI~~ 
fibrins, ~Y lIsing recornbll1:lnt celiularlXJI[ (A") (jrx) Loewy u/mL UA] f-~1~ 
~r hy uSing plasma (lOS [,oewy Il/ml) ~s the ~Ol1l'ce of the tX][L The C!ell, 
!l1lklllg.reaClion \vas terminated ~y adding 10 voilimes o.f 2C{ aCl'iic acid ,n 
Incuhatlllg ,at 1'00111 temperalllle Jor [. h. Illsolublc_ materwl Via~ rCll10vt(j h 
ccntrifugat\On and the fibrinogen rematnmg III solutIOn ,yas quantiti.:ci SPt'clr~ 
photoHII:Lliullly ~IL 230 nnl. The;;e data Viere plotted and rate of cro~s-lllki~" 
l?r, insoluble matenalil111111 was calculated from the steepest slope of lh~; 
plot~, Alternatively, the reactions ,vere terminated by adding an eqJal volllrr,~ 
of2X Laemmll sample bldTcr With I l;{ ~-Illercaptuethan(ll, ilild the prullUlllol 
the reaction were analYfed hy SDS-PAGE employing the discontinll<JuS blilltr 
sySlL'm of Laemmli (64) on 9% polyacryLunidc gels. Gels were sbincu \Iilh 
Oj~;;, Coomassic Brilliant Bille R250, [n cerLail1 control experimellt'; \JE\ll~ 
iodoacetamick fO.5 m:\ .. 1 final L'ollCelltralion) was added to inhihii D~IlI!t 
tXIlla activity (57), SOJlle crosslinklllg reaction:; weIe carried OJI at r~Jm 
lcmpcrature for up to 5 days. The resulting gels ,,'crc washed, digested wilh 
plasmin (0.2 caseinolytic l[hnL final) and the digestion products wel\' anah'leu 
for D trimer and D tetramer hy sns-p . .\GF. (19, 66) . 
Factor XIII or XIlJa activity was also determined lIsing N,N'-dime[hlj. 
casein and l~C-cadaverine as sub~traLcs as described by Lon.nd et al. 167i. 
Briefly, N,N' -dimethylcQsein (O.Y::G) ,md PC-cadaverine (1.5 mM) III 50 m\t 
Tris. 100 ]1]\1 :.'\faCL 5 mt\"1 CaCi,) U.5 m:\.f OTT. 0.5 mM Pl\ISF, )0 KlUiml 
I'rasyloL pH 7.4 was mixed with various amounts or fX1I1 m fXllla 10 iii 
100 Loev,"y ulml: 0 to O. 124 f.L\1) and incuhated at room temperatllre. At seicct, 
ed times 100 fl.1 or the reaction mixture was s]X!ited on WhcllJllan ~M\I lillr[ 
paper and immediately plunged into ice cold 10% tricJ1loroacelic acid. Tttt, 
lillcr papers were washed [\, .. icc will] ice cold Y{, trichloroacetic acid, once \Iilh 
ethanol:acetonc (l: I), and then with icc colel acctonc. After air dlYlIl~ [iii: 
sample ladioaClivities were counted . ~ 
The possible Ideasc of fibrinopepticb and the factor Xlll activmioll pepliJ~ 
doring the crosslinking reaction was e~,lmined by HPLC (46) using a Vai,n 
Vista model 500n system Clllltrolled bv a Vmim mmld 401 micrmmlCcs)iX_ 
Fibrinogen n mgin;n ill 50 mM Tris, -I !XlmM NaG 5 m?vf Cact 0.5 m~l 
OTT. D.S mM P\1SF, 10 KIUlml Tra~ylol, 0.1 % PEG 6000, pII 7.4. The real" 
tion was initiated by adding tXIII (850 Loewy \liml; 1.0 /l1U and lhe mi.,[Ufe 
was incubaLcd al mom temperallire. Control reactions were irLitiakd bl [I" 
addition of [XIII (850 Loc\,"), uimi) and thromblll ((j,05 uiml). AT scl~,\·teJ 
intervals the reactioll \l,;as terminated by' incubation in a hailing wate! bath f(lf 
10 min. The samples were cl~rified by centrifugation and applied w an AI[o 
C18 reverse-phase column (\146 X ~5 cm: Rainin Instruments Co, Wuhum. 
MA) (:LlllilihI'Jted with 90% O.OS3 \;1 sodiulll phospllak, pH ~.1. l(j~;:, acriOnl' 
trill' {buffer Al. Elution \vas performed isocmtically ror rhe first 10 min using] 
Illixtlll'e lOf 85% bUller A/151}( buffer B (buffer 8; 60((( 0.083 :",1 sodium ph~),' 
phate, pH 3.1,40% acetonitrile) followed by a linear gradicill rnll1l SY,{ hu(f([ 
A/L'ick buffer B to 10iJi hurrer A190% buff:::r B over 50 min. Pepti,\e) 11;'[<' 
detected with a \Vatel's detector s,~l al205 nm. 
Results 
The time course of plasma facto!.' Xlll-medialed crosslil~king (li 
fibrinogen is presented in Fig. 1. Gamma dimcrs are ror1l1u] in lit 
reaction mixture wiLhin 5 mi; of incubation at room temperature anJ 
a-polymers begin to appem at 10 min. Under the conditions enlployeJ. 
complete'Y chain crosslinking rCljuired incubation limes of grcUiCI' lhan 
12 h, D trimers and D letrarners, the markers for"y trimer and -I tdJ'JI1l([ 
formation, could be detected in plasmic digests of tXIII crmsjinketi 
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n,~, I Time course of plasma factor XJJJ-mcdialcd crosslinking of fibrino-
~en. Fibrinogen I (3 mg/mn and tXIlI (100 J .Ut\l,.'y uiml) \>,'ere incubared for the 
indicaled times as described in ~Iaterials and Methods. Reactions w;:re tenni-
nat~d by :l(kling gel ~ample buffer containing I (;f, ~-IllLTCaplOl'rhilnoL anel the 
rnxhlcb were -eparated by SDS-PAGE 
Ca Ion Concentration (mM) 
o 0.050.1 0.250.5 1 2 3 4 5 
" ct-polymer 
/Y-dimer 
___ _______ XIH 
--A('f 
".iiiiii •• ii ... ::~ 1\ 
rig,2 Cnlcium iun sensitivity of fibrinogen crosslinking by plasm~ fXIII_ Fi-
brinogen 1 (\ mgfmll and fXIIl (I UU Loewy ufml) were incubated as described 
til i\btcrials and Mcthoos with the indicated concenlrations o1CaC12, Rcacliulls 
Ilerc terminated hy adding gel sample bllffer eontainlllg 1 t)'~ ~-meITaploelha­
[[01. allLithe products were separated by SUS-PAGE 
t'ibrinogell gels as early as 24 h into the incubalion period and tbeir con-
Centrations incrca~ed \vilb increasing times of incllbation (data not 
\10WI1J. Crosslinking and gel formation was nor due to contaminating 
lhrombin activating the proteills since lleither fibrinupeptidc A or B nor 
:he ["Xlii acriv<liion peptide could be detected in the rcaction mixtures 
Dr in the [-actor XIII preparations alone even when the concentration 0[" 
reactants \vas increased S.5-fold and rhe inCllhaiion was allowed to 
lX'cur ror 96 h (results not shm ... n). 
Siebcniist et a1.: Factor XIII Crossllnking 01' Fibrinogen ami Fibrin 
Table I Fibrinogen Cl"OSSllllking at vari,llls concentrations of factor Xlii 
XIII Concentration Percent Soluble Fibrinogen 
(Lot\."y u/ml) @ 6 hrs @ 24 hr.s 
o 100 + 1.9 100 + 2.9 
61.7+3.3 13.9 ± S.2 
43,2 + 2.3 S_3 + 4_8 
100 24.7 + 3.8 S.7 I 3,] 
150 16.0 ± 2.4 4.7 ± 2.4 
200 8.3 +4.3 3.S + (,6 
Fibrinogen I (3 mg/rnl'l al:d the indicated level of XI [I in SD rn~'l Tris, 
IC() mM :\'aCl. 5 mM CaC12. 0.5 mM OTT. 0.5 m\1 P~v'lSL I () KHiiml 
Trasylol, pH 7.4 burrer wel'e inCllbated at room tcmperature. The 
reaction was terminated by tIle addition DC 2S'{ acdic acid. imolllblc 
material removed by ccntrifugation, and the fibrinogen remaining 
in solutiol] quantificd spcCU"ophotollletrically al 280 nl1l. \1ean ± 
standard deviation or Cour independent trials 
The amount of fibrinogen incorporated into insoluble gels was 
direclly proporlionalto the amount of tXllI prescnt in thc reaction mix ~ 
ture (Tal)le I). CalciL1m ions arc absolutely requircd for fXIIl-ll1cdiatcd 
crosslinking of fihrinogen, since in the abscncc of calcium no cross-
linking \\i<1S detected even aftcr 24 11 (Fig, 2), COl1eenlrations of Ca> as 
low as 50 ).1M were sufficient 1.0 produce an easily measurable degree 
of "I chain crosslin king and the amount of "I dimer formation increased 
with increasing Ca> cOllcenlrations. Alpha polymcrs wcrc detcctcd in 
tbe reaction mixtures at Ca2t concentrations above I mM. Optimal 
fibrinogen crosslinking \l,'as achieved at 24 h at 5 111M Ca2t or higher. 
'I'hiol reagents, though not required for plasma IXlIT-medlated fihri-
nogcn gelation, ncvertbeless increased the amount of fihrinogen ren-
dered insoluble (Table 2), Adding OTT at a concentration of 2.5 /l-M 
increased the amount of fibrinogen incoqx)Tated into the gel five-fold 
and >80% gelation \-vas achieved at 500 /l-J..'1 DTT. ~-~kreapioelhanol 
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Fig.3 Fibrinogell crossiinking by plasma tXIII (AB':I or I"eulmbinanl cellu-
lar IXlll (A,). hbrinugcn I [3 mg/ml) was incubated for the indicated timcs 
with pl<islml Ixm (100 Loewy Llim]) 01" witll recombinant Cellular fXlll 
(1 (Xl 1.oewy 11l1irs/ml) as drscribed ill Materials ([11(1 \t1ethotis. Reactillll' were 
tcrminated by adding acetic acid and the fibrinogen remaining in sulution WJS 
l]uanliCied ~pectr()ph()tometrically. I.) pli:sma IXIII; (e) rl'combinant cdlulilr 
Ixm, MeGin of 6 independent expt'riment~ 
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{ ab{e 2 J"hiol ;:-nh<l ll(;emenr of 
Percent Soluble Fiblinoven mediated fihrinog~n {;l1)sslinking 
Cu" , mM Thiol, fll\1 ])'IT B-MSH Cvsleinc 
() 0 100 + 2.2 100 + 2.9 100 + 1.8 
4 0 94.4 + 0.8 94.1 ± 0 .:1 95.8 + O.R 
4 2.5 74.3 + 3.9 88.6 + 2.0 94.2 +0.5 
4 5 64.6 + 7.5 77.5 ± 5.4 93 .9 + 2.7 
4 10 53.7 + 6 .8 7 1.7+:1 .4 86.0 + 2.0 
4 2S 46.3 ± 8.2 64.2 ± 4 .1 78.7 + 3.0 
4 50 39.0 + fL? 55 .3 ± 2.3 72.2 + 3.9 
4 100 33.7 + 8.6 19.7 + 5.0 64. 1 + 3.3 
4 2,0 22.1 + 4 .5 42 .7 + 5.2 57 .8 + 2.5 
4 500 18.5+ 2. 1 36.4 + 5.3 53.9 + 2.5 
4 1000 15.6 ± 8.6 32. 1 ± 2.0 51.4 ± 2.6 
Fibrinog~n It3 rug/ml) and XIII (100 Loewy u/ml) in 50 mM Tris, 100 mM N:lCI, 05 m\'! 
P~ ... lSI-. 10 Kll':/ml Trasylol, pI! 7.4 huffer, were incllb.1fed wilh Ihl'. indit:<l led C(l ilcelll raijo ll ~ 
of C.1 ~· and thiol rcagent for 6 h at room temperatufC. The reaction was termin:lloo by the 
!lc1dltion of 2,} acetic acid. insoluble. material rcmov,,;U by cent ri fugation , lllld the fi brinogen 
f~nKlin i ng in solution quanti fied ~lX'cuupholOmelrical1y al 280 nm. Mean ± standard devi ation 
of six indepe,ndelll triah 
and cysteine also caused an increase in the amount of insoluble fibrino-
gen. but til cy were 2 to 3 fold less effective than DTT at any given 
concentration. 
The kinetics of crosslinking hy recombinant cellular fac tor XIII. (A]) 
were ~o1llewh a t different than with plasma IXIII (Fig. 3). There was 
H lag in the iniTial rate of librinogen nosslinking by plasma fX!ll nOi 
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Fig. 4 Fihrinogen or fibrin crossJinking hy plasma tXlll or fX lIla. Fibri n,').. 
gt=1I t or soluhili/td fibrin 1 t3 mglml) and IA III or thrombin act ivaled tXUI:1 
(100 Loewy uillll) were incuhated lor the ind icatcd limes OI~ deS(' ribcd ill 
Malcriab and Mcthod~. Reaclions were· tcmlirraled by adding acc-lic acid and 
(he fihri nogen remai ning. in .~o ltllion was quantified speclroplrolourd rir.:ally. 
(_ , fibrinogen & fXlLL (e l fibrinogen & iXHIa; (.A) fihlin & fXnl: 
(X) fihrin & fXllla. Mean of 6 il lclepelli.lelll e.xperimcms 
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observed \\:ith cellular lXIII, suggesting th aI. Ihc pre~ence of B ~ uhllliits 
had retarded the onsel or plasma fXII I-mediated cruss Jinking. :.l eva· 
theJess, the crosslink.ing rate with plasma rX II[ I;:vcnlualJ y sliI"j)l ssed 
tlrat of cell ular fX Ill. and at its max imum wa~ twice that of recombinant 
cellular fXrrL again suggesti ng that the non-cataly tic B )ubunits h~ 
Olodjfied the cTosshnking activity of the Al stlblln i t ~ . 
100 
• 
80 FiIH";noogen 1 t 
:c 
~ 
(; 60 ~ 
.= 
c 
• 40 ~ 
• 0. 
20 
t 
Fibrinogen 2 
'~~~~--~1~2~0--~1 8~0C--~2~4~0 ---3~0~Oc--:llio 00 
Incubation Time (mIn) 
f is. 5 Fi bri nogen 1 or fibrifio.~cn 2 ero:,~l i.n k.i ng by pt a.~mu IXJll F it"lri ll{lf~ 
I Of fibrinogen 2 (3 mglml) and IXII I ( Ino Locwy u/ml ) were incllbareJ '-ortt.~ 
indicated iime.s as d~{;ribed in \1alc·rials [Ind .\1elhods. i{c:1clions wer~ lenlli· 
nat..-d by addi ng a{;etic acid and lhe fi brillogen remain ing in solutioll W;):i 
quanti l'jeJ speclrophotometrjcall y. (_ ) fib rinogen (: (e ) tlblinogen2 . .\kant,f 
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The rate of crosslin king catalyzed by plasma lXTlT and lhrombill-
.\([inlted tXlIla are compared in Fig, 4, With fibrinogen as substratc. 
;'ac(Ol' XIIl displayed a longcr lag period than did fXIIIa, but eventually 
'[) rate approached 750., that or IXlIla. The rate of fibrin erosslinklllg 
~\' faclor XUJ v ... a~ almost X times faster than it was with fibrinogen. and 
[I~ rale of fihrin erosslinking by fXIIIa was about 6 times faster than 
II'ith fibrinogen. In the case or fibrin erosslinking, as had been the case 
II'ith tibrinogcn, factor fXlIl exhibited an initial lag phase compared 
Wilh tXHla., but eventually its crosslinking rale [Jecame virtually the 
),llllt' as that of fXIIIa. 
The fact that fibl'inogen 2 binds plasma factor XlII B subunits (lJj 
SLl£"2ested that non-covalent assoCIation of H and A snhllnits on fibrino-
'Tt';l~ 2 might rL111ction to supprcss fXIII crosslinking activity. Indeed. 
~\'hel1 fibrinogen 2 \vas incubated with plasma fXl11 the lag time of the 
(['osslin~ing reaction was nearly twice as long as Lhat observed \vith 
fibrinogen 1 and the maximum rate of fibrinogen crosslinking was 
uecreased 3.5-fold (Fig. 5). This suggesLs lhat the complex formed 
tll.'twecn tibrinoge1l2 and plasma 1'X1ll eCfecLively slowed the develop-
ment of crmslinking activity of the catalytic Al subunits by slmving 
their release from the complex. 
The relative rate of crosslinking by fXIII and fXlIla ",las very differ-
tilt with :.i.N'-dimethylcasein as a substrale cOlI\pared with fibrinogen 
or fibrin (Fig. 6). At an activity level of 100 Loe\l,ly uimL thrombin-
adil'ateJ IXII1a incorporated 14C-cadaverinc into casein at least]O rold 
mort: rapidly than did the factor XUl zymogen, v,rhich had very little 
adi',"1ty. These findings suggcst that the robust transglutaminase activity 
displaycd by of factor XIII lS specific for fibrinogen or fibrin as sub-
~lrates since it occurs vcry poorly with a nOll-physiological substrate 
like casein. 
il seemed possible that a small amount of facLor XIII had become 
activated during the purification process I~alheit undetectable by SDS-
PAGE:!. To assess this possibility, fibrinogen crosslinking with pooled 
hllman plasilla as the IXIII source was compared with the pllriJ"ied 
plasma lXIII (Fig. 7). The rcaction mixtures containing the plasma as 
the source of t'XIII formed insoluble crosslinked fiblinogen at a faster 
rate and to a larger extent than did samples containing an equivalent 
p{1tential activity of purified rxm. The effect was more marked in Ibe 
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Fig. (j '~C-cadavcrine incorporation into .'l~'-dimethy!l:a~in by plasma 
rXIII 0)' rXllia. N,\!' dirnethylcasein (0.5%) ancl1+C-cadaverine fl.5 mrVi) wus 
Ini.~ed with tX1I1 or fXllla (100 Lun>.'), uJml) and incubated at room tempern-
:ure. Al sl.'kc!ed times ]00 IJ-l of the readiun mixlul·1.' was spotted 011 \Vhatman 
1~,'t\1 filter papel' alld treated as described in the methods section, (_j fXIIIa: 
Ie) lXIIL Mean or 3 independent exp:riments 
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Fi<~. 7 Fibrillogell nosslillkillg Illcdinted by purified factor XIII or plasma. 
Fibrinugen 1 (200 IJ-l) was crosslinkcd under the standard buffer condiuons by 
adding 0.4 mM Drr (p,mel A) or 0.U5 111M DTT (panci B) and 50 IJ-l of puri-
ried Ixm diluted to 105 Loewy uiml or by adding 50 IJ.I or pooled normal 
human pla~ma containing 105 u/ml fXIII, Fibrinogen 1 cOlicentraLion~ in the 
pbsma-colltaining samples were adjusted so lhallhc final fibrinogen concen-
tration \vas 3 mg/ml. The rcactiollS wefe incubaled al room temperature for the 
indicakd limes, lerlllillakd by adding acetic acid, and the fibrinogen rc:mailling 
in sulutiun was qmmtified spectropholOrnetrically, 1:_) plasma factor Xlll: 
(e) plasma. :\'Iean of 3 indepelldelll experiments 
presence of 0.4 mM DTT (panel A) than it was at 0.05 mM OTT (panel 
B). Gclalion was not attributable [0 thromhin activity in the plasrna-
containing s,nnples since control mix.tures ill which the fXIII was in-
hibiLed by NElvl or iodoacetamide (0.5 mM) did not form uncrosslinked 
clots dnring a 24 h incubation period (not shown), These results suggest 
that if anything, thc purification process Illily lead to il l'eductlOn in the 
intrinsic crosslinking potential of factor XIII, 
Discussion 
These present studies show that fibrinogen can be cnlsslillked and 
rendered insoluble during a Ca2+ dependent, thiol-enhanced reaction 
catalyzed by plasllla factor XIII. In our hands, an easily appreciable 
level o/' crosslinking can he achieved at Ca> at cOllccntrmiuns ahove 
SO ~M, and that the effect is augmented at OTT concentralions above 
2.5 ",dvl. The rcsults show that: I, cellular and plasma I'actor XIII both 
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crosslink fibrinogen; 2, fibrin is crossli nked faster thUIl fibrinogen; 
1, fi brinogen 2, the carrier of plitsma fXm, is crossli nked more slowly 
and to a It!sser t!.'aellithall fibrinogen I; 4, the fXIJI purifil.:'ll it)l\ pro(,;cs~ 
itself does nol accou nt ror the observed crosslin king activ ity of lXIII, 
since plasm:l could more than adequately replat:i: puri fied fXlII :IS a 
soun:c of activity; 5, when fibrinogen or fibrin is crossli nked by plusm:t 
fXIII there is always an inil ial lag in rhe developmenl of the max imal 
crosslinkin£ ratc: 6, [XIII c("()sslinking activity is spccifi<.: for fibrinogen 
(or fibri n) as suhslrale(s) inasmuch as only very low lran5glutamill:l,<.;e 
activi ty was c!eteclcd when cadaverine and ~,N' -dillie thyka~dn W~~fC 
employed as substrates in the reaction, These data suggest th,lt dll ri ng 
the hlg phase of the reaction fibrinogen suhstrate mol ecules bind D.l or 
Ilcar the act ive siLe or· lxm causing a conformali onal changc Ihal 
renders the "zymogen" catalytically active and that may also lead to 
dissociation of A and B subunits, Fibrinogen 2 slows the rate of cross-
linking by binding the B subunits of the zymogen and re!-,training the 
diffusion of the catalytic A 'iubunits, 
Polgar et al. 16R) reponed that "platelet" (cellular) D(flT (A) could 
Ix. actinlted by high conccllIratiolls of NaCI or KCI and Iha! aeliv~I Li uJl 
could he prevented by B subunits. \1uszbek et al. (69. 70) have al;;o 
shown that "platelet" lXIII could be activated intracellularly in a throm-
bi n-independelH manner. All of these act ivation phenomena required 
Ca:!t, occUlred after secretion and plalelet <lg..l!regation wert: cumpleted. 
and resu lted in UIC crosslillking of cel lular proteins. In tile l<t llcr two 
studies (69 ,70) the authors postulated that the activation process might 
require the inl.eraction of "platelet" fXfH \vith some othcr cellul ar 
proTein, The pre,enl I'esults suggesl Ihe platelet component that could 
serve aii ,'mhstrate for uncleaved fXITI, may be fibrinogen itsdf. A COIl -
l'ormutionul change in factor XIII induced by fihrin(ogen) in the pre-
sence of Cu:!t may be more important in the non-catalytic activation at' 
fX 11l than is removal of the activation pepLide it self, since X-ray 
cl'Y~taliograph ic swJies llll lhrombin-cleaved rel:umbinant cellular 
tXIU ( .~) de.monSlraLed 110 large conf0l111ational changes in the mole-
cu le (7 1). 
The pathophysiological ro le pJil)'ed by nnactivllted factor XII I in the 
circulation is unclcar. but sevcral considc-rations suggesr that it i~ a 
read ily available source of fibrin cros!)li nking activ it)' during early 
phases of fi bl;n elOi formation. Plasma factor XlU is cleaved rel:ll ively 
slowly by thrombin compared to [hrombill cleavage of fibrinogell 
(47, 72), <Ind tlUl \> crosslink.i ng aClivity due tu fXllla format ion would 
he min imally available during early phases of throlilbill-rIlcuialtd d ot 
fl)l1llClI i(\n, Moreover, si n<.:e fib rin is a mllch better substrate for cross-
linking than is librinogen 1)4, 35, Lhis study ), lhe cro~s lill king pOlemi (li 
of dot~ i ncorporatcd fX TIJ vlould he selective for fihrin ()Ver fi brinogen, 
Rc(;c,lIt ~tudie-s of Ancrod infLlsiolls in lmtnnns (Tl) ~ I rong l )' supports 
rhe idea that plasma fXIII is a [X)tent source of cros.,l inking activity, 
Allcrod is a purified snake vGl10m GnzymG from the Malnyrtll pit viper 
Ca{{osel£lsnla rhot/ostoliUl that clots ribt'inogen by sckctively cleaving 
Jibrinopeptide A, Lnlike thrombin, it has no capacity LO cleave fac-
tor XlII (74), In thei.r study, DcmpOe el al. (3) llleasun:u the cJTccls of 
Ancl'lJ(1 ad minis tration to normal volunteers, and early in the cour~e of 
the infus ion Ihey found sohlhle crosslink e( l fi brin c-omplexe$. followed 
somewhat later by the appearance of a cm~sli n ked fi blin ctcgrada~io ll 
product, D dimer. Since there-was 00 evidence that thrombin genera· 
lion had oc(;urred. these crosslinked products must havc arisen through 
tht constillllivc crosslinking activity of fac tor XIII acting on Ancrud-
induced fibrin. 
Th~re are several observatiolls that probably rC\rl'allhe footprinr of 
fXlII activity in plasma, r\ormal pla<;ma fibrinogen contains readil y 
measl1I'ablc iU1l0unts of intermole.cularly crossli nl-.;eLl "I dimcl's and 
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intramolcc ulmly cl'Osslinl-.;ed Aa-"I helcriXl imc rs (75), The relative con. 
tribution by lXIII versus a tis<;ne transglut1lminuse in forming th~t 
crosslinked fihrinogens cannul be lJj st ingu i ~hcd , but nc\,ert hek'ss raise, 
suspicion that fXllJ i<; invul ved ill their fonllutioJl . l't?-aliliplasmin i; 
anolher possible 'iubstrate- for the intri nsic activity of ciKulalillg !"XIII 
It has heen known for some rime that [here i ~ .1 potent plasmin iohibi: 
tory acti vity bound to fi bri nogen (76). Although Ihe speci fic C' lI tity:o 
fi brinogen accounti ng for thal acti vity was not identified , we iflfer from 
more recent studies (see belmv) that the inhibitory ,«,'Iivity \\t,L): aUri. 
bUlable to the presence of a 2-antipla~min ~'ovalcntl y crossUnktrllo 
fibrinogen, Recently, Siebenli sl Cl aI, (77) demonstrated lhe pr('~l:I1(e of 
covalently bound li2-antipbstnill in lIo]']nal f'ibrinogell as '11-'1:11 as in ~ 
dysfibrinogenem;a known as fibrinoge.n Cedar Rapids (,'yR275C), We 
specnl8te that the Ct2-antiplasmin had occome: im'orporated i11\O Cibrino. 
gen through the action or fXTfT, ill it lllanner th;t!. is entirely anali)g()li~, 10 
The crosslinki ng reaction that was demonstrated between fibrin llgcnand 
tXllIa by Tchinose and Aoki (7S), Fllnher, the const itutive cro;;\!in l in2 
activity of fXUI might conceivably also account for some or a l l llf l ~~ 
cMsJin.k.ed tihrinogen products that arc founu ill bnscmcllI mCmbraTli\ 
(79) and ill atherosclerotic plaques (80). [0 ,u.lditiun, the imrillsic aeTjyi lr 
of IX1l1 could measllrably contribute to formation uf the cro'!lsl inked 
fibrin(ogcn) 'Y chains that occur in pathologkaJ "cryofibrinogen" com-
plexes (81,82). 
Familial MedilcrraLlean Fever (FMf) is lin herediTary disease in 
which cryofiblinogenemia is known to occur (83.84) and is a~sociated 
with increased fib rill{ogen) cros~ljnking (84), The genc respow,: jblc ~or 
cau ~ing the disease has been cloned (HS ), but the p,lthogcne~ i ~ or (he 
disorder remains llIKcl1ain, I:MP is characterized by illte,rmittcll l febrile 
episodes, abdominal pain, pleurisy, and arthritis (Rfi), A substanlial pro· 
portion of individuals with untreated disease eventually deveiop amy-
loidosis and renal failure (83), Although cryotihrinogencmia occur, 
commonly in FMF subjects. and is usually regarded as a marklA for a 
hypercl)agulablc or thrombotic state (81, 82), F~1f pati ent~ do not 
manifest a thrombophilic phenotype (83), The <': l'yufibri lloge.n precip:-
tarcs found in FMF contain high lc:wls or "'Tos~ li nkcd fibrinogen 'Y :Ilxl 
(A) (l chains (84). and it seems possible that .\lome of the ciinic<ll m;m:-
fcstatiolls of FMF could be rdated to enhanced IXIII activity ltadingl(l 
fo rmalion of increased levels of circulating crossl inked fi bri n~}ten. 
Moaddcl I:t al. (87) recently cuncluded from the re<;ulls or sedimer.-
fation equi li brium experiments OIl plasma fXlll-librinogen !nixmrcs 
containi ng I mtvI CaCI]" thal high affiill ty non-covalent complex~s had 
funned between tXIII and either fibrinogen I ("I", l'A) Of fih!'inogcn ~ 
("t;\ , "I')' In the case o/" Clbrinogen I. the apparent as~ociation (Olbtatll 
(K) \liaS 1,3 X lOS , and \vas caicium-deperlc\el1t b~(.: allse no COlllp lexo 
formed in the presence or EDTt\. , The apparell ( Ku for the fibl'iilogen ~ 
("I A' -y ' )-factnr XIII "complex" Vias nearly thirty-fold higher. ~,6 X II)~ 
These Kit values seem quite hi gh in their own light for a pre~ urtlcd non· 
covalent molecular interaction, especially considering an earli er n:port 
that only -(-containing fibrinogen 1 hud any dClllonqrahk I)inciing 
affinity for factor XII[ (9). Their interpretation thaI nOIl-covabn (om-
plexes had fonned depended upon the assump tion that unactivo.lt:u fac-
lOr XIII could not promote cru~sliJ1king of ti hlinogcn in the prc,\cna-01 
C t1 .. , which we show here 10 he incorrect. 'l1ll1s, conclusions C01lCt11l-
jng non-covalent complex fonnalion belween [XIII <IIlU IIbrino,:!en will 
have to be validated hy a different set of experiments, sinc\! it s~t."n~ 
certain thm factor xm-cl1)sslitlkcd tlbrinogen molecu l~ had bt\'~ 
produced during the course of Lhcil' scdimen!:llioll (:qll lli briuIII L:Xp~·n· 
mCllts , 
Undcr normal conditions onlv small :unoun ts 01" crossli nked hhri(Il
'· 
gell molecules anc! other protei ~s, such as ~]-'Hltip l a smin. are found in 
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la~01a. TIlc typical calcium concentrations used in tbese cxpcrimc1lLs 
Pre comparable to those that exist in plasma. Moreover, there are thiols 
a . I' I 
'n the circulatlOll such as g lItathlOlle, that can serve to augment t 1e 
;la~elillC eJlzymatic pulcntial of [XIII. Recent reports indicaLe thaL thiol 
levels ill plasma can be greaLet- than 3m 11M (88). It therefore seems 
ler" likely thM plasma contallls "inhibitory clements" that supprcss or 
1l1odulate the illtrinsic fXllI activity. One ~IICh factor \Vllllid he rihrino-
rell2 itself, given that the "/' chain-containing, tXlIf-binding form of 
fibrinogen becomes crosslinked hy fXU] at a much 100ver rate than 
Ilbrinogcll 1. The high levels of B subunits that arc present in plasma 
l11i£ht provide a second suppressive elemenl, since B subunits are 
kn;wn to prevelll lhruillbin-ilidependelit activation of "platelet" fac-
tor XlIl (68} and their presence results in a lag in the onsct of cross-
linking by plasma tXIII. Another impo11ant down-regulating effect 
would be the fact that fihl'in is a better substrate ror fXm crosslinking 
tban is fibnnogen (34, 35, this study) and therefore the rate at which 
(rosslin~il1g takes place in the normal fibrinogen-containing plasma 
enl'ironment is typically much lower than it \vould be if fibrin were 
present. 
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